Ian W. Flinn

Ian Flinn, MD, talks about recent developments in chronic lymphocytic leukemia treatment, emerging therapies that show promise, and how Tennessee Oncology’s new research center will improve access to clinical trials for more patients.

Ian Flinn, MD, talks about...

01/10/2024

Journal of Clinical Pathways

Patterns of duvelisib‐induced lymphocytosis in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high‐risk factors, in the DUO trial

Purpose of the Study: Lymphocytosis is a defining feature of chronic lymphocytic leukemia (CLL) and recognized as a class effect of treatment with B‐cell receptor pathway inhibitors....

Shih Chen ;

Samantha Hidy ;

Johnathan Pachter ;

Jennifer R. Brown ;

Matthew S. Davids , MD, MMSc;

David T. Weaver ;

Stephanie Lustgarten ;

Jacqueline Barrientos ;

Ian W. Flinn ;

Amanda Cashen ;

Nicholas Chiorazzi ;

10/23/2019

PERSPECTIVE: A Randomized, Phase 3 Study of Ibrutinib-Rituximab Versus Placebo-Rituximab Combination Therapy for First-Line Treatment of Follicular Lymphoma

Background: Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma originating from germinal-center B cells.

Leonie Gordon , MD;

Simon Rule ;

Robert Chen ;

Ian W. Flinn ;

Long Kwei ;

Alvina Chu ;

Nathan Fowler ;

10/19/2020

Patterns of duvelisib‐induced lymphocytosis in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high‐risk factors, in the DUO trial

Purpose of the Study: Lymphocytosis is a defining feature of chronic lymphocytic leukemia (CLL) and recognized as a class effect of treatment with B‐cell receptor pathway inhibitors....

Jacqueline Barrientos ;

Ian W. Flinn ;

Amanda Cashen ;

Nicholas Chiorazzi ;

Shih Chen ;

Samantha Hidy ;

Johnathan Pachter ;

Jennifer R. Brown ;

Matthew S. Davids , MD, MMSc;

David T. Weaver ;

Stephanie Lustgarten ;

10/23/2019

An improved benefit‐risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a ...

Constantine S. Tam ;

Ulrich Jager ;

Paolo Ghia ;

Stephan Stilgenbauer ;

Peter Hillmen ;

Marco Montillo ;

Florence Cymbalista ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Matthew S. Davids , MD, MMSc;

Ian W. Flinn ;

Julio Delgado ;

Bryone J. Kuss ;

10/23/2019

An improved benefit‐risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a ...

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Ian W. Flinn ;

Peter Hillmen ;

Julio Delgado ;

Marco Montillo ;

Bryone J. Kuss ;

Florence Cymbalista ;

Constantine S. Tam ;

Ulrich Jager ;

Paolo Ghia ;

Stephan Stilgenbauer ;

Matthew S. Davids , MD, MMSc;

10/23/2019

An improved benefit‐risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a ...

Hagop Youssoufian ;

Ian W. Flinn ;

Julio Delgado ;

Bryone J. Kuss ;

Constantine S. Tam ;

Ulrich Jager ;

Paolo Ghia ;

Stephan Stilgenbauer ;

Peter Hillmen ;

Marco Montillo ;

Florence Cymbalista ;

David T. Weaver ;

Matthew S. Davids , MD, MMSc;

Stephanie Lustgarten ;

10/23/2019

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Purpose of the Study: Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/smal...

Julio Delgado ;

Bryone J. Kuss ;

Constantine S. Tam ;

Francesc Bosch ;

Ulrich Jager ;

Paolo Ghia ;

Florence Cymalista ;

Stephan Stilgenbauer ;

Fritz Offner ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;